Arrowhead Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Arrowhead Pharmaceuticals with us this morning. And from the company, we have Chris Anzalone, CEO; as well as Vince Anzalone, Vice President. With that, I'll turn it over to you, Chris.
Questions & Answers
To start here, as you look to 2020, you're looking to move into extra hepatic tissues. And I think we saw your data sets last year and this year as well as you look at liver directed, but can you help us understand, as you go outside of liver-directed tissues, what are the key aspects of your technology and data to date that lend confidence to be able to achieve this?
Yes. Thanks very much, Salveen, and thanks very much for having us. It's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
